PeptideScanner
U.S. label record↗Metabolic↗

Dulaglutide↗

Related names in cited records: Trulicity↗

A GLP-1 receptor agonist. This profile cites a Trulicity label.↗

Citation markers ↗ open the public records supporting the adjacent statements.

Correction · September 15, 2026

We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope. 1

This version supersedes public version 2.

Start here

The evidence at a glance

What is its status in the cited records?

U.S. label record. The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

Status sources checked through September 15, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.↗↗↗

What the reviewed sources report

REWIND reported fewer composite cardiovascular events with dulaglutide; all-cause mortality did not differ significantly. AWARD-PEDS reported improved glycemic control without a between-group BMI benefit. AWARD-7 studied a kidney-disease population, with glycemic control as its primary outcome.↗↗↗

What remains unresolved?

  • What do longer-term studies establish for populations and outcomes outside these three selected reports?↗↗↗
  • How do later trial analyses relate to their original cohorts, and which findings have independent replication?↗↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Trulicity · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The label covers glycemic control with diet and exercise in adults and children aged ten years and older with type 2 diabetes. Its cardiovascular indication concerns adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Label: 1 ↗

Which safety limits matter?

The boxed warning reports thyroid C-cell tumors in rats, with uncertain human relevance. Contraindications include a personal or family history of medullary thyroid carcinoma, MEN 2 and serious hypersensitivity. Other warnings include pancreatitis, hypoglycemia with insulin or insulin secretagogues, kidney injury from volume depletion, severe gastrointestinal reactions, retinopathy complications, gallbladder disease and aspiration during anesthesia or deep sedation. Label: boxed warning, 4, 5 ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

TRULICITY (dulaglutide) injection, solution · SPL version 62 · published 2026-08-10

Label ZIP SHA-256: 0be61134741cd12e32e7ea35d42b7ad3d11a0a333b31e08005cf499692d46779. Extracted XML SHA-256: 2a790740cae6415ba5160d0c578d599e26decb426a6f5c59d99803bb53b227d5.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

European medicine records · 1 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Catalog-name and calibrated alias discovery for human evidence review. Complete query retrieval is separate from clinical eligibility, study-family linkage and appraisal.

1286 retrieved · 3 included · 0 excluded · 1283 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"Dulaglutide"[Title/Abstract] OR "Trulicity"[Title/Abstract]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:09:29.527094+00:00 · HTTP 200 · SHA-256 c009befb7c7b789edc478284d80169749cf275598e546e88b7da1b38ad9e70a6.

  • Retrieved IDs completely represent this query response, not all relevant literature. Additional aliases, references and non-PubMed sources require separate searches.
  • Unscreened records may include animal or cell experiments, reviews, secondary analyses, mixtures, protocols and unrelated name matches.
  • Study-family mappings use available declared registry IDs; unresolved mappings do not create independent trial counts. Full-text, corrections and registry comparison remain separate work.

Showing 25 of 1286 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 35658022 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT02963766.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 dc1082dfd33187fb63389cc88f10e6d5687b40ee291e3ef7c129e6cfe27f6246.

  2. PubMed 31189511 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01394952.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 935add390b4c371ea1cc07cd33e4e8ced2482ff54ebdbca13b79c8f5e499402a.

  3. PubMed 29910024 — include: Selected published human report; abstract reviewed. Full-text and study-family appraisal remain separate. Study families: NCT01621178.
    Bibliographic record recheck · 2026-09-15

    The selected PubMed XML payload matches the previous reviewed snapshot. This is a metadata recheck, not a new appraisal or a finding that no corrections exist. Open PubMed record ↗

    SHA-256 31bd83dd9c06f67f4c208db9e37ece0be0360231598fbfc2ad6d135281db9297.

  4. PubMed 42730869 — not screened: Name-query match awaiting clinical eligibility screening.
  5. PubMed 42729958 — not screened: Name-query match awaiting clinical eligibility screening.
  6. PubMed 42726083 — not screened: Name-query match awaiting clinical eligibility screening.
  7. PubMed 42706739 — not screened: Name-query match awaiting clinical eligibility screening.
  8. PubMed 42692277 — not screened: Name-query match awaiting clinical eligibility screening.
  9. PubMed 42687799 — not screened: Name-query match awaiting clinical eligibility screening.
  10. PubMed 42682267 — not screened: Name-query match awaiting clinical eligibility screening.
  11. PubMed 42652097 — not screened: Name-query match awaiting clinical eligibility screening.
  12. PubMed 42645931 — not screened: Name-query match awaiting clinical eligibility screening.
  13. PubMed 42629417 — not screened: Name-query match awaiting clinical eligibility screening.
  14. PubMed 42626264 — not screened: Name-query match awaiting clinical eligibility screening.
  15. PubMed 42624955 — not screened: Name-query match awaiting clinical eligibility screening.
  16. PubMed 42623541 — not screened: Name-query match awaiting clinical eligibility screening.
  17. PubMed 42618994 — not screened: Name-query match awaiting clinical eligibility screening.
  18. PubMed 42618811 — not screened: Name-query match awaiting clinical eligibility screening.
  19. PubMed 42609010 — not screened: Name-query match awaiting clinical eligibility screening.
  20. PubMed 42608321 — not screened: Name-query match awaiting clinical eligibility screening.
  21. PubMed 42607855 — not screened: Name-query match awaiting clinical eligibility screening.
  22. PubMed 30000038 — not screened: Name-query match awaiting clinical eligibility screening.
  23. PubMed 42594084 — not screened: Name-query match awaiting clinical eligibility screening.
  24. PubMed 42584027 — not screened: Name-query match awaiting clinical eligibility screening.
  25. PubMed 42575344 — not screened: Name-query match awaiting clinical eligibility screening.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"DULAGLUTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:12.358576+00:00 · HTTP 200 · SHA-256 0abaa427fb4db3165c438bb185019c2f40442ef52fe5b0d4fddb3ba7998fb456.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA BLA125469 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: DULAGLUTIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Dulaglutide", "Trulicity"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/002825 — include: EMA feed product Trulicity; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

23 retrieved · 14 included · 0 excluded · 9 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Dulaglutide", "Trulicity"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 23 of 23 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 3547 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-10311-201609 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  2. EMA 7481 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Medicine overview
  3. EMA 15349 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  4. EMA 28747 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - All Authorised presentations
  5. EMA 29560 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Public assessment report
  6. EMA 33131 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Risk-management-plan summary
  7. EMA 39535 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-00010311-201709 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  8. EMA 45943 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-II-0040 : EPAR - Assessment report - Variation
  9. EMA 50024 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-X-0045 : EPAR - Assessment report - Variation
  10. EMA 51787 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-PSUSA-10311-202009 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)
  11. EMA 58037 — include: Document linked by EMA product number; content unappraised. Trulicity-H-C-2825-II-0065 : EPAR - Assessment report - Variation
  12. EMA 3409 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  13. EMA 72360 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Procedural steps taken and scientific information after authorisation
  14. EMA 11584 — include: Document linked by EMA product number; content unappraised. Trulicity : EPAR - Product information
  15. EMA 35491 — not screened: Title-name match awaiting identity and document review. CHMP summary of positive opinion for Trulicity
  16. EMA 45471 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of positive opinion for Trulicity (II-40)
  17. EMA 57411 — not screened: Title-name match awaiting identity and document review. CHMP post-authorisation summary of opinion for Trulicity (II-65)
  18. EMA 57625 — not screened: Title-name match awaiting identity and document review. P/0409/2021 : EMA decision of 29 October 2021 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M06)
  19. EMA 50586 — not screened: Title-name match awaiting identity and document review. P/0175/2020: EMA decision of 13 May 2020 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M05)
  20. EMA 14233 — not screened: Title-name match awaiting identity and document review. P/0227/2016: EMA decision of 26 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M04)
  21. EMA 12783 — not screened: Title-name match awaiting identity and document review. P/0017/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity), (EMEA-000783-PIP01-09-M03)
  22. EMA 18730 — not screened: Title-name match awaiting identity and document review. P/0039/2014: EMA decision of 5 March 2014 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (EMEA-000783-PIP01-09-M01)
  23. EMA 31033 — not screened: Title-name match awaiting identity and document review. P/0105/2015: EMA decision of 29 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for dulaglutide (Trulicity) (EMEA-000783-PIP01-09-M02)

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Dulaglutide", "Trulicity"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    147 retrieved · 0 included · 0 excluded · 147 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Dulaglutide" OR "Trulicity"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:25:14.826563+00:00 · HTTP 200 · SHA-256 27e35f8e0f27e1adfb4ce9c1d23e125c8f4bce5bd6850acbb7054929ce95c8e1.

    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:25:16.146760+00:00 · HTTP 200 · SHA-256 2258f651089bb57bb913b595112eb06316c213dcacdba19ba5890e5f48843c76.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 147 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT05377333 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT06500143 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT05140694 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT03204396 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT07276763 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT03363906 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT06901648 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT05946148 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT06779929 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT07537088 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT05990374 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT01511393 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT06611904 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT05478707 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT01558271 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT05564039 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT07398222 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT07619495 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT07313813 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT04189848 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT05492305 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT01001104 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT01253304 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT06120556 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT05348122 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Read the full Human Evidence Review

    Supervised synthesis

    What do selected human studies report about Dulaglutide?

    Manually reviewed September 15, 2026 · version 1

    Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

    Three selected randomized reports cover cardiovascular events in older adults with type 2 diabetes, glycemic outcomes in youths, and glycemic and kidney measures in adults with chronic kidney disease. This overview does not cover the full AWARD program or all later analyses.123

    Bottom line from this bounded source set

    REWIND reported fewer composite cardiovascular events with dulaglutide; all-cause mortality did not differ significantly. AWARD-PEDS reported improved glycemic control without a between-group BMI benefit. AWARD-7 studied a kidney-disease population, with glycemic control as its primary outcome.123

    Reviewed study record

    REWIND: cardiovascular outcomes

    Design

    A blinded randomized placebo-controlled trial followed participants for a median of 5.4 years.1

    Population

    The trial enrolled 9,901 adults aged at least 50 with type 2 diabetes and cardiovascular disease or risk factors.1

    Outcomes reported

    The primary cardiovascular composite occurred in 12.0% with dulaglutide versus 13.4% with placebo (hazard ratio 0.88; 95% CI 0.79–0.99). Gastrointestinal adverse events were more frequent with dulaglutide.1

    Limitations

    The composite combines different outcomes and does not imply improvement in every component. All-cause mortality was not significantly different; these results do not establish effects in people without type 2 diabetes.1

    Reviewed study record

    AWARD-PEDS: glycemic control in youths

    Design

    A blinded randomized placebo-controlled study evaluated a 26-week primary endpoint, followed by an open-label extension.2

    Population

    The trial randomized 154 participants aged 10 to under 18 with type 2 diabetes.2

    Outcomes reported

    Glycated hemoglobin decreased in the dulaglutide groups and increased with placebo. BMI change did not differ between groups; gastrointestinal adverse events were more frequent with dulaglutide.2

    Limitations

    The primary outcome was glycemic control, not cardiovascular events or long-term complications. The short blinded period limits longer-term conclusions; PubMed links subsequent correspondence.2

    Reviewed study record

    AWARD-7: diabetes with chronic kidney disease

    Design

    An open-label randomized trial compared dulaglutide with insulin glargine, with insulin lispro in all groups, over 52 weeks.3

    Population

    The study randomized 577 adults with type 2 diabetes and stage 3–4 chronic kidney disease.3

    Outcomes reported

    Dulaglutide met the prespecified noninferiority criterion for glycated hemoglobin change at 26 weeks. At 52 weeks, estimated filtration rates were higher with dulaglutide; nausea and diarrhea were more frequent.3

    Limitations

    Kidney measures were secondary outcomes. This trial cannot establish a general prevention claim for kidney failure or isolate the effects of background insulin treatment.3

    Reviewed source set

    1. PubMed · 31189511Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. ↗PubMed PMID 31189511 · EFetch XML reviewed 2026-09-15 · payload SHA-256 935add390b4c371ea1cc07cd33e4e8ced2482ff54ebdbca13b79c8f5e499402a
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s0140-6736(19)31149-3. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    2. PubMed · 35658022Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes. ↗PubMed PMID 35658022 · EFetch XML reviewed 2026-09-15 · payload SHA-256 dc1082dfd33187fb63389cc88f10e6d5687b40ee291e3ef7c129e6cfe27f6246
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2204601. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    3. PubMed · 29910024Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. ↗PubMed PMID 29910024 · EFetch XML reviewed 2026-09-15 · payload SHA-256 31bd83dd9c06f67f4c208db9e37ece0be0360231598fbfc2ad6d135281db9297
      No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2213-8587(18)30104-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Dulaglutide?

    U.S. label record. The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

    The cited status sources were checked through September 15, 2026. This answer changes only through the profile’s visible version and correction history.

    91Dated records38PubMed records10Trial records41Regulatory records

    Evidence present

    What records are connected here?

    Evidence lanes
    4
    Source years
    13
    Drugs@FDA applications
    1

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Latest source-dated record

    What changed most recently at a cited source?

    Clinical trials · source date September 4, 2026

    ClinicalTrials.gov record NCT06851962↗Added to PeptideScanner September 9, 2026

    Coverage gaps

    What remains unknown or unsupported?

    All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Open the complete timeline →Browse all connected recordsFollow via RSS
    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Dulaglutide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    91Selected dated records
    92Connected citations
    13Populated source years2014–2026
    4/4Record lanes present
    Clinical trials10Open matching records →Literature metadata38Open matching records →Regulatory41Open matching records →Safety2Open matching records →

    Registered human studies

    Trial composition

    4 of 10 selected trial records include at least one phase value; 5 of 10 include a status value in the retained structured contract.

    63 public history versions connect to 8 of these trial records across 11 submitted years. Open the record-history collection →

    PhasesPhase 1 1Phase 2 1Phase 3 1Phase 4 1
    Status at observationCompleted 3Recruiting 2

    A phase value is unavailable here for 6 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 5 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    14 of 38 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 12Research Support, Non-U.S. Gov't 3Case Reports 2Letter 2Randomized Controlled Trial 2Comment 1Comparative Study 1Multicenter Study 1Review 1

    Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    1
    FDA Federal Register documents
    1
    DailyMed SPL versions
    39
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    91

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts

    Research hub

    Explore the Dulaglutide evidence record

    Open all 91 records →
    91Dated records
    4Evidence types
    91Cited public sources
    13Source years

    Change ledger

    Recently changed for Dulaglutide

    Open all 93 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Correction

    Dulaglutide profile

    We refreshed this profile's label citation to the reviewed SPL version 62, published 2026-08-10. Earlier profile versions retain their original label citations. The product-specific label account identifies its reviewed scope.

    PeptideScanner change date
    September 15, 2026
    Evidence lane
    Profile
    Open the profile version →Compare the preserved prior version →Open machine-readable lineage →
    Cited source
    Record added

    ClinicalTrials.gov record NCT06851962

    PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.

    PeptideScanner change date
    September 9, 2026
    Cited source date
    September 4, 2026
    Evidence lane
    Clinical trials
    Open the cited record →
    Cited source
    Record added

    ClinicalTrials.gov record NCT07313813

    PeptideScanner retained ClinicalTrials.gov record NCT07313813 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was dulaglutide.

    PeptideScanner change date
    September 9, 2026
    Cited source date
    August 21, 2026
    Evidence lane
    Clinical trials
    Open the cited record →
    Cited source

    Official-source collections

    Source records for Dulaglutide

    Open the full research atlas →
    PubMed38

    14 with attributed title, venue, publication-date, and type metadata.

    Journal Article (12)Research Support, Non-U.S. Gov't (3)Case Reports (2)
    1. Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process.Pharmaceuticals (Basel, Switzerland) · 2025 12 16
    2. Inequity in adherence to empagliflozin and dulaglutide for type 2 diabetes in Aotearoa New Zealand.Diabetes, obesity & metabolism · 2025 06 24
    3. Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy.Acta diabetologica · 2024 08 10
    Explore all selected literature →
    ClinicalTrials.gov10

    63 public history versions across these dated registry records; status labels apply only to each cited observation.

    Recruiting history (36)Completed history (12)Not Yet Recruiting history (9)
    Current at observation (2)Completed at observation (8)
    Type 2 Diabetes (2)Diabetes Mellitus Type 2 (1)Diabetes Mellitus, Type 1 (1)Phase 1 (1)Phase 2 (1)Completed (3)Recruiting (2)
    Dulaglutide · Drug (5)
    1. NCT06851962Registry update September 4, 2026 · completed at observation
    2. NCT07313813Registry update August 21, 2026 · completed at observation
    3. NCT05478707Registry update August 12, 2026 · current at observation
    Explore all selected trial records →Explore all public record history →
    FDA enforcement reports2

    Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

    1. D-0884-2022Class II · report date 2022-05-25
    2. D-0773-2021Class II · report date 2021-09-01
    Explore all exact FDA enforcement reports →
    DailyMed SPL history39

    Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

    1. SPL version 62Published 2026-08-10 · ZIP SHA-256 0be61134741c…
    2. SPL version 60Published 2026-03-25 · ZIP SHA-256 e99d651404ff…
    3. SPL version 59Published 2025-12-22 · ZIP SHA-256 49deea60c570…
    4. SPL version 57Published 2025-06-30 · ZIP SHA-256 ca68633d203a…
    5. SPL version 56Published 2025-06-09 · ZIP SHA-256 9cacd61af535…
    Explore all DailyMed label versions →

    Counts and links describe PeptideScanner’s selected records. They are not rankings and do not establish research quality, safety, effectiveness, or medical relevance.

    Evidence types

    Coverage by source year

    Selected records span September 18, 2014 to September 4, 2026.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Glucagon13 shared source years308 dated records · 4 evidence typesLeuprolide13 shared source years215 dated records · 4 evidence typesLiraglutide13 shared source years167 dated records · 4 evidence typesOctreotide13 shared source years160 dated records · 4 evidence types

    These dates come from selected source records and PubMed metadata. They are not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Evidence summary

    What the cited records say

    The cited DailyMed label identifies Dulaglutide and contains the product's official indications and warnings. This profile links to the label without restating it as medical guidance.↗

    This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

    Cited context

    Related records

    Organizations named in cited records

    • U.S. National Library of Medicine↗

    Dated source history

    Updates connected to this profile

    Open the full cross-source timeline →

    1. Clinical trials

      ClinicalTrials.gov record NCT06851962↗

      PeptideScanner retained ClinicalTrials.gov record NCT06851962 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was dulaglutide.↗

    2. Clinical trials

      ClinicalTrials.gov record NCT07313813↗

      PeptideScanner retained ClinicalTrials.gov record NCT07313813 at 2026-09-09T19:17:17.407Z. Its registry update date was 2026-08-21, and PeptideScanner's reviewed identity mapping was dulaglutide.↗

    3. Clinical trials

      ClinicalTrials.gov record NCT05478707↗

      PeptideScanner retained ClinicalTrials.gov record NCT05478707 at 2026-08-13T05:54:14.860Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was dulaglutide.↗

    4. Regulatory

      Dulaglutide DailyMed SPL version 62↗

      DailyMed lists Structured Product Labeling version 62 for the reviewed Dulaglutide label family with a published date of 2026-08-10. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

    5. Clinical trials

      ClinicalTrials.gov record NCT06739122↗

      PeptideScanner retained ClinicalTrials.gov record NCT06739122 at 2026-08-13T05:52:27.010Z. Its registry update date was 2026-08-07, and PeptideScanner's reviewed identity mapping was dulaglutide.↗

    6. Literature metadata

      PubMed record PMID 41988866↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41988866 at 2026-08-10T18:13:46.880Z. PubMed recorded a metadata revision date of 2026-07-15 and an Entrez history date of 2026-04-16. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    7. Clinical trials

      ClinicalTrials.gov record NCT07417631↗

      PeptideScanner retained ClinicalTrials.gov record NCT07417631 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-10, and PeptideScanner's reviewed identity mapping was dulaglutide.↗

    8. Literature metadata

      PubMed record PMID 37743669↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 37743669 at 2026-08-10T18:13:32.327Z. PubMed recorded a metadata revision date of 2026-07-06 and an Entrez history date of 2023-09-25. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    9. Literature metadata

      PubMed record PMID 38954432↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38954432 at 2026-07-30T16:14:08.766Z. PubMed recorded a metadata revision date of 2026-06-22 and an Entrez history date of 2024-07-02. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    10. Literature metadata

      PubMed record PMID 39718468↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39718468 at 2026-07-30T16:14:08.915Z. PubMed recorded a metadata revision date of 2026-06-20 and an Entrez history date of 2024-12-24. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    11. Literature metadata

      PubMed record PMID 38600796↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38600796 at 2026-07-30T16:14:06.917Z. PubMed recorded a metadata revision date of 2026-06-19 and an Entrez history date of 2024-04-11. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    12. Literature metadata

      PubMed record PMID 38715179↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38715179 at 2026-07-30T16:14:06.944Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-05-07. PeptideScanner associated this retained record with the identity slug dulaglutide. These dates describe PubMed metadata history, not the article's original publication date.↗

    Public beta · Selective source coverageNot medical advice · No dosing or purchasing guidance